Oh, those numbers, so the Mesoblast spend of $590m, nah, can't...

Oh, those numbers, so the Mesoblast spend of $590m, nah, can't be real numbers can they, not possible (somebody here supplied them) lets round it up to $800m for fun. Getting back to a point, is say $800m an efficient use of funds compared to the industry minimum average of $6b to get 3 products over the line?

So to work with % figure, 1% of 6b is 6b/100, so 1% = 60m. Then divide 800 by 60.

So $800m is a little over 13% of the industry spend of $6b to get to about the same stage. Now can you elaborate why my inflated figure of $800m is poor funding use?

If you get desperate you could double or treble the percentage if you need to support your story. It would still come out to pretty good management compared to other biopharma figures, and that is using the lower figure of $2b rather than $3b per product times 3.

We'll get more numbers to play with in the morning.